Recent advances in multifunctional dendrimer-based nanoprobes for breast cancer theranostics

References

• De Cicco P, Catani MV, Gasperi V, et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019;11(7):1514.
   PubMed Web of Science ®Google Scholar
• Hussain Z, Rahim MA, Jan N, et al. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: improved pharmacokinetics, cell internalization and anticancer efficacy. J Control Release. 2021;335:130–157.
   PubMed Web of Science ®Google Scholar
• Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and Meta-analysis. Breast Cancer Res Treat. 2019;176(3):519–533.
   PubMed Web of Science ®Google Scholar
• WHO. Breast cancer. WHO; 2018.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019, CA. Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• WHO | Breast cancer, (n.d.).
   Google Scholar
• Luo Y, Prestwich G. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2002;2(3):209–226.
   PubMed Web of Science ®Google Scholar
• Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol. 2008;229(1):121–134.
   PubMed Web of Science ®Google Scholar
• Kaur H, Kesharwani P. Advanced nanomedicine approaches applied for treatment of skin carcinoma. J Control Release. 2021;337:589–611.
   PubMed Web of Science ®Google Scholar
• Wu JS, Li JX, Shu N, et al. A polyamidoamine (PAMAM) derivative dendrimer with high loading capacity of TLR7/8 agonist for improved cancer immunotherapy. Nano Res. 2022;15(1):510–518.
   Web of Science ®Google Scholar
• Sharma G, Anabousi S, Ehrhardt C, et al. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target. 2006;14(5):301–310.
   PubMed Web of Science ®Google Scholar
• Nitheesh Y, Pradhan R, Hejmady S, et al. Surface engineered nanocarriers for the management of breast cancer. Mater Sci Eng C Mater Biol Appl. 2021;130:112441.
   PubMed Web of Science ®Google Scholar
• Singh S, Numan A, Somaily HH, et al. Nano-enabled strategies to combat methicillin-resistant Staphylococcus aureus. Mater Sci Eng C Mater Biol Appl. 2021;129:112384.
   PubMed Web of Science ®Google Scholar
• Mishra P, Handa M, Ujjwal RR, et al. Potential of nanoparticulate based delivery systems for effective management of alopecia. Colloids Surf B Biointerfaces. 2021;208:112050.
   PubMed Web of Science ®Google Scholar
• Gad A, Kydd J, Piel B, et al. Targeting cancer using polymeric nanoparticle mediated combination chemotherapy. Int J Nanomed Nanosurg. 2016. doi:10.16966/2470-3206.116.
   PubMedGoogle Scholar
• Zhuo F, Abourehab MAS, Hussain Z. Hyaluronic acid decorated tacrolimus-loaded nanoparticles: efficient approach to maximize dermal targeting and anti-dermatitis efficacy. Carbohydr Polym. 2018;197:478–489.
   PubMed Web of Science ®Google Scholar
• Dawoud M, Abourehab MAS, Abdou R. Monoolein cubic nanoparticles as novel carriers for docetaxel. J. Drug Deliv. Sci. Technol. 2020;56:101501.
   Web of Science ®Google Scholar
• Bashir M, Ahmad J, Asif M, et al. Nanoemulgel, an innovative carrier for diflunisal topical delivery with profound anti-Inflammatory effect: in vitro and in vivo evaluation. Int J Nanomed. 2021;16:1457–1472.
   PubMed Web of Science ®Google Scholar
• Islam N, Irfan M, Zahoor AF, et al. Improved bioavailability of ebastine through development of transfersomal oral films. Pharmaceutics. 2021;13(8):1315.
   PubMed Web of Science ®Google Scholar
• Du YQ, Yang XX, Li WL, et al. A cancer-targeted drug delivery system developed with gold nanoparticle mediated DNA-doxorubicin conjugates. RSC Adv. 2014;4(66):34830–34835.
   Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bull. 2015;5(2):151–159.
   PubMedGoogle Scholar
• Zhou Q, Zhang L, Yang T, et al. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomed. 2018;13:2921–2942.
   PubMed Web of Science ®Google Scholar
• Amjad MW, Kesharwani P, Mohd Amin MCI, et al. Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy. Prog. Polym. Sci. 2017;64:154–181.
   Web of Science ®Google Scholar
• Abourehab MAS, Ahmed OAA, Balata GF, et al. Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood–brain barrier. IJN. 2018;ume 13:3679–3687.
   Google Scholar
• Liu CC, Zhao JJ, Zhang R, et al. Multifunctionalization of graphene and graphene oxide for controlled release and targeted delivery of anticancer drugs. Am J Transl Res. 2017;9(12):5197–5219.
   PubMed Web of Science ®Google Scholar
• Elhissi AMA, Ahmed W, Hassan IU, et al. Carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv. 2012;2012:837327–837310.
   PubMedGoogle Scholar
• Chadar R, Afzal O, Alqahtani SM, et al. Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy. Colloids Surf B Biointerfaces. 2021;208:112044.
   PubMed Web of Science ®Google Scholar
• Abedi-Gaballu F, Dehghan G, Ghaffari M, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018;12:177–190.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Md S, Kesharwani P. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. J Control Release. 2021;340:221–242.
   PubMed Web of Science ®Google Scholar
• Singh V, Sahebkar A, Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. Eur. Polym. J. 2021;158:110683.
   Web of Science ®Google Scholar
• Singh V, Kesharwani P. Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics. J. Biomater Sci Polym Ed. 2021;1–29. https://doi.org/10.1080/09205063.2021.1938859.
   Google Scholar
• Dubey SK, Kali M, Hejmady S, et al. Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer. Eur J Pharm Sci. 2021;164:105890.
   PubMed Web of Science ®Google Scholar
• Gorain B, Tekade M, Kesharwani P, et al. The use of nanoscaffolds and dendrimers in tissue engineering. Drug Discov. Today. 2017;22(4):652–664.
   PubMed Web of Science ®Google Scholar
• Zhu J, Shi X. Dendrimer-based nanodevices for targeted drug delivery applications. J Mater Chem B. 2013;1(34):4199–4211.
   PubMed Web of Science ®Google Scholar
• Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 2005;30(3–4):294–324.
   Web of Science ®Google Scholar
• Wang H, Huang Q, Chang H, et al. Stimuli-responsive dendrimers in drug delivery. Biomater Sci. 2016;4(3):375–390.
   PubMed Web of Science ®Google Scholar
• Sarin H. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies. Recent Pat CNS Drug Discov. 2010;5(3):239–252.
   PubMedGoogle Scholar
• Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2016;11:1–12.
   PubMed Web of Science ®Google Scholar
• Sharma A, Gautam SP, Gupta AK. Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery. Bioorg Med Chem. 2011;19(11):3341–3346.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014;39(2):268–307.
   Web of Science ®Google Scholar
• Kesharwani P, Banerjee S, Gupta U, et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater. Today. 2015;18(10):565–572.
   Web of Science ®Google Scholar
• Gorzkiewicz M, Konopka M, Janaszewska A, et al. Application of new lysine-based peptide dendrimers D3K2 and D3G2 for gene delivery: specific cytotoxicity to cancer cells and transfection in vitro. Bioorg Chem. 2020;95:103504.
   PubMed Web of Science ®Google Scholar
• Gupta U, Dwivedi SKD, Bid HK, et al. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm. 2010;393(1–2):185–196.[20382210.
   PubMedGoogle Scholar
• Kaur D, Jain K, Mehra NK, et al. A review on comparative study of PPI and PAMAM dendrimers. J. Nanoparticle Res. 2016;18:146.
   Web of Science ®Google Scholar
• Kharwade R, More S, Warokar A, et al. Starburst pamam dendrimers: synthetic approaches, surface modifications, and biomedical applications. Arab. J. Chem. 2020;13(7):6009–6039.
   Web of Science ®Google Scholar
• Mignani S, Rodrigues J, Tomas H, et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev. 2018;47(2):514–532.
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Bechra HM, Derkar GK, et al. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009;38(3):185–196.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond). 2014;9(15):2291–2308. ).
   PubMed Web of Science ®Google Scholar
• Cancer Pathophysiology, (n.d.).
   Google Scholar
• Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339(oct13 1):b3410–898.
   PubMedGoogle Scholar
• Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283–298.
   PubMedGoogle Scholar
• NCI SEER public-use data: applications and limitations in oncology research - PubMed, (n.d.).
   Google Scholar
• A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western Australia - PubMed, (n.d.).
   Google Scholar
• Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–399.
   PubMed Web of Science ®Google Scholar
• Malins DC, Gunselman SJ, Holmes EH, et al. The etiology of breast cancer characteristic alterations in hydroxyl radical‐induced dna base lesions during oncogenesis with potential for evaluating incidence risk. Cancer. 1993;71(10):3036–3043.
   PubMed Web of Science ®Google Scholar
• Núñez C, Capelo JL, Igrejas G, et al. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016;97:34–50.
   PubMed Web of Science ®Google Scholar
• Woo SH, Seo SK, Park Y, et al. Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. Oncotarget. 2016;7(37):59809–59819.
   PubMedGoogle Scholar
• Breast Cancer Pathophysiology | Oncology Nurses Quality Improvement Series, (n.d.).
   Google Scholar
• Shokooh MK, Emami F, Duwa R, et al. Triple-negative breast cancer treatment meets nanoparticles: Current status and future direction. J. Drug Deliv. Sci. Technol. 2022;71:103274.
   Web of Science ®Google Scholar
• American Cancer Society. Breast Cancer Risk Factors You Cannot Change - Google Search, (n.d.).
   Google Scholar
• Hu J, Vecchia CL, de Groh M, Canadian Cancer Registries Epidemiology Research Group, et al. Dietary cholesterol intake and cancer. Ann Oncol. 2012;23(2):491–500.
   PubMed Web of Science ®Google Scholar
• Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–1098.
   PubMed Web of Science ®Google Scholar
• DuSell CD, Umetani M, Shaul PW, et al. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22(1):65–77.
   PubMedGoogle Scholar
• 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen - Google Search, (n.d.).
   Google Scholar
• Nelson ER, yi Chang C, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014;25(12):649–655.
   PubMed Web of Science ®Google Scholar
• ational Cancer Institute. Genetics of Breast and Gynecological Cancers - Google Search, (n.d.).
   Google Scholar
• American Cancer Society. Breast Cancer HER2 Status. Available at: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed: September 9, 2019. - Google Search, (n.d.).
   Google Scholar
• Rakovich TY, Mahfoud OK, Mohamed BM, et al. Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells. ACS Nano. 2014;8(6):5682–5695.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Gothwal A, Kesharwani P, et al. Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery. Drug Discov. Today. 2017;22(2):314–326.
   PubMed Web of Science ®Google Scholar
• Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. Obstet. Gynecol. Surv. 2013;68(3):201–202.
   Web of Science ®Google Scholar
• Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev. Ind. Pharm. 2015;41:1393–1399.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Choudhury H, Meher JG, et al. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog. Mater. Sci. 2019;103:484–508.
   Web of Science ®Google Scholar
• Su S, Tian Y, Li Y, et al. “Triple-punch” strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy. ACS Nano. 2015;9(2):1367–1378.
   PubMed Web of Science ®Google Scholar
• Thanikachalam PV, Ramamurthy S, Wong ZW, et al. Current attempts to implement microRNA-based diagnostics and therapy in cardiovascular and metabolic disease: a promising future. Drug Discov Today. 2018;23(3):460–480.
   PubMed Web of Science ®Google Scholar
• Singh S, Hassan D, Aldawsari HM, et al. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223–229.
   PubMed Web of Science ®Google Scholar
• Gorain B, Choudhury H, Pandey M, et al. Dendrimer-based nanocarriers in lung cancer therapy. In: Nanotechnology-based targeted Drug Delivery Systems for Lung Cancer. Elsevier; 2019. p. 161–192.
   Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov. Today. 2015;20:536–547.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Pandey M, Chin PX, et al. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res. 2018;8(5):1545–1563.
   PubMed Web of Science ®Google Scholar
• Gorain B, Choudhury H, Nair AB, et al. Theranostic application of nanoemulsions in chemotherapy. Drug Discov Today. 2020;25(7):1174–1188.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Pandey M, Wen LP, et al. Folic acid conjugated nanocarriers for efficient targetability and promising anticancer efficacy for treatment of breast cancer: a review of recent updates. Curr. Pharm. Des. 2020;26:5365–5379.
   PubMed Web of Science ®Google Scholar
• Luong D, Kesharwani P, Deshmukh R, et al. PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. 2016;43:14–29.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhao Y, Han M, et al. Codendrimer (PAG) from polyamidoamine (PAMAM) and oligoethylene glycols (OEG) dendron: evaluation as drug carrier. J Mater Chem B. 2013;1(44):6078–6084.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Guo Y, Li R, et al. Methotrexate nanoparticles prepared with codendrimer from polyamidoamine (PAMAM) and oligoethylene glycols (OEG) dendrons: antitumor efficacy in vitro and in vivo. Sci Rep. 2016;6:28983.
   PubMed Web of Science ®Google Scholar
• Oddone N, Lecot N, Fernández M, et al. In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer. J. Nanobiotechnology. 2016;14:45. doi:10.1186/s12951-016-0197-6
   PubMed Web of Science ®Google Scholar
• Peng J, Zhou W, Xia X, et al. Encapsulation of acetylshikonin by polyamidoamine dendrimers for preparing prominent nanoparticles. AAPS PharmSciTech. 2014;15(2):425–433.
   PubMed Web of Science ®Google Scholar
• Sahoo RK, Gothwal A, Rani S, et al. PEGylated dendrimer mediated delivery of bortezomib: drug conjugation versus encapsulation. Int J Pharm. 2020;584:119389.
   PubMedGoogle Scholar
• Li T, Smet M, Dehaen W, et al. Selenium-platinum coordination dendrimers with controlled anti-Cancer activity. ACS Appl Mater Interfaces. 2016;8(6):3609–3614.
   PubMed Web of Science ®Google Scholar
• Gurdag S, Khandare J, Stapels S, et al. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem. 2006;17(2):275–283.
   PubMed Web of Science ®Google Scholar
• Bielawski K, Bielawska A, Muszyńska A, et al. Cytotoxic activity of G3 PAMAM-NH 2 dendrimer-chlorambucil conjugate in human breast cancer cells. Environ Toxicol Pharmacol. 2011;32(3):364–372.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman MA, Al-Abd AM. Thermoresponsive dendrimers based on oligoethylene glycols: design, synthesis and cytotoxic activity against MCF-7 breast cancer cells. Eur J Med Chem. 2013;69:848–854.
   PubMed Web of Science ®Google Scholar
• Shan H, Dou W, Zhang Y, et al. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale. 2020;12(43):22268–22280.
   PubMed Web of Science ®Google Scholar
• Taghavi Pourianazar N, Gunduz U. CpG oligodeoxynucleotide-loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells. Biomed Pharmacother. 2016;78:81–91.
   PubMed Web of Science ®Google Scholar
• Nosrati H, Adibtabar M, Sharafi A, et al. PAMAM-modified citric acid-coated magnetic nanoparticles as pH sensitive biocompatible carrier against human breast cancer cells. Drug Dev Ind Pharm. 2018;44(8):1377–1384.
   PubMed Web of Science ®Google Scholar
• Kojima C, Suehiro T, Watanabe K, et al. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater. 2013;9(3):5673–5680.
   PubMed Web of Science ®Google Scholar
• Khodadust R, Unsoy G, Gunduz U. Development of poly (I: C) modified doxorubicin loaded magnetic dendrimer nanoparticles for targeted combination therapy. Biomed Pharmacother. 2014;68(8):979–987.
   PubMed Web of Science ®Google Scholar
• Parsian M, Mutlu P, Yalcin S, et al. Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery. Int J Pharm. 2016;515(1-2):104–113.
   PubMedGoogle Scholar
• Matai I, Sachdev A, Gopinath P. Multicomponent 5-fluorouracil loaded PAMAM stabilized-silver nanocomposites synergistically induce apoptosis in human cancer cells. Biomater Sci. 2015;3(3):457–468.
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, et al. Dendrimer toxicity: let’s meet the challenge. Int J Pharm. 2010;394(1–2):122–142.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Gothwal A, Iyer AK, et al. Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discov Today. 2018;23(2):300–314.
   PubMed Web of Science ®Google Scholar
• Dwivedi N, Shah J, Mishra V, et al. Dendrimer-mediated approaches for the treatment of brain tumor. J Biomater Sci Polym Ed. 2016;27(7):557–580.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. Drug Discov. Today. 2015;20(5):497–499.
   PubMed Web of Science ®Google Scholar
• Sung SA, Kim DH, Oh KH, et al. The role of cathepsin B in peritoneal fibrosis due to peritoneal dialysis. Int J Nephrol. 2019;2019:4150656.
   PubMed Web of Science ®Google Scholar
• Dheer D, Nicolas J, Shankar R. Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases. Adv Drug Deliv Rev. 2019;151-152:130–151.
   PubMed Web of Science ®Google Scholar
• Turk V, Turk B, Turk D. New embo members’ review: lysosomal cysteine proteases: facts and opportunities. Embo J. 2001;20(17):4629–4633.
   PubMed Web of Science ®Google Scholar
• Zhang C, Pan D, Li J, et al. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Acta Biomater. 2017;55:153–162.
   PubMed Web of Science ®Google Scholar
• Zhang C, Pan D, Luo K, et al. Peptide dendrimer-doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Adv Healthc Mater. 2014;3(8):1299–1308.
   PubMed Web of Science ®Google Scholar
• Thakur S, Tekade RK, Kesharwani P, et al. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J. Nanoparticle Res. 2013;15:1625. doi:10.1007/s11051-013-1625-2
   Web of Science ®Google Scholar
• Li N, Cai H, Jiang L, et al. Enzyme-sensitive and amphiphilic PEGylated dendrimer-paclitaxel prodrug-based nanoparticles for enhanced stability and anticancer efficacy. ACS Appl Mater Interfaces. 2017;9(8):6865–6877.
   PubMed Web of Science ®Google Scholar
• Tao JJ, Castel P, Radosevic-Robin N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci. Signal. 2014;7(318):1–10.
   Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.
   PubMed Web of Science ®Google Scholar
• Masuda H, Zhang D, Bartholomeusz C, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331–345.
   PubMed Web of Science ®Google Scholar
• Liu C, Gao H, Zhao Z, et al. Improved tumor targeting and penetration by a dual-functional poly(amidoamine) dendrimer for the therapy of triple-negative breast cancer. J. Mater. Chem. B. 2019;7(23):3724–3736. )
   Web of Science ®Google Scholar
• Thakur S, Kesharwani P, Tekade RK, et al. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer (Guildf). 2015;59:67–92.
   Web of Science ®Google Scholar
• Bertuzzi DL, Braga CB, Perli G, et al. Water-soluble well-defined bifunctional ferrocenyl dendrimer with anti-cancer activity. Eur. J. Inorg. Chem. 2022;2022:e202101084.
   Web of Science ®Google Scholar
• Morath I, Jung C, Lévêque R, et al. Differential recruitment of CD44 isoforms by ERBB ligands reveals an involvement of CD44 in breast cancer. Oncogene. 2018;37(11):1472–1484.
   PubMed Web of Science ®Google Scholar
• Jeannot V, Gauche C, Mazzaferro S, et al. Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. J Control Release. 2018;275:117–128.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7-8):605–618.
   PubMed Web of Science ®Google Scholar
• Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007;72(4):430–441.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Xie L, Mao G, et al. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf B Biointerfaces. 2015;136:413–423.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Pandey M, Yin TH, et al. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology. Mater. Sci. Eng. C. 2019;101:596–613.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Gorain B, Pandey M, et al. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int. J. Pharm. 2019;565:509–522.
   PubMedGoogle Scholar
• Guo XL, Kang XX, Wang YQ, et al. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Acta Biomater. 2019;84:367–377.
   PubMed Web of Science ®Google Scholar
• Wu P, Sun Y, Dong W, et al. Enhanced anti-tumor efficacy of hyaluronic acid modified nanocomposites combined with sonochemotherapy against subcutaneous and metastatic breast tumors. Nanoscale. 2019;11(24):11470–11483.
   PubMed Web of Science ®Google Scholar
• Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–4964.
   PubMed Web of Science ®Google Scholar
• Corcoran KE, Trzaska KA, Fernandes H, et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 2008;3(6):e2563–10.
   PubMed Web of Science ®Google Scholar
• Ablett MP, O'Brien CS, Sims AH, et al. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget. 2014;5(3):599–612.
   PubMedGoogle Scholar
• Tamamura H, Tsutsumi H, Masuno H, et al. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr Med Chem. 2007;14(1):93–102.
   PubMed Web of Science ®Google Scholar
• Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–56.
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Anuchapreeda S, Sarisuta N. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition. Eur J Pharm Biopharm. 2017;119:310–321.
   PubMed Web of Science ®Google Scholar
• Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34(6):791–808.
   PubMed Web of Science ®Google Scholar
• Senkus E, Cardoso F, Pagani O. Time for more optimism in metastatic breast cancer? Cancer Treat Rev. 2014;40(2):220–228.
   PubMed Web of Science ®Google Scholar
• Figueroa-Magalhães MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast. 2014;23(2):128–136.
   PubMed Web of Science ®Google Scholar
• Pinto AC, Ades F, de Azambuja E, et al. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013;22:S152–S155.
   PubMed Web of Science ®Google Scholar
• Chan C, Cai Z, Reilly RM. Trastuzumab labeled to high specific activity with 111in by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells. Pharm Res. 2013;30(8):1999–2009.
   PubMed Web of Science ®Google Scholar
• Cai Z, Chattopadhyay N, Yang K, et al. 111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection. Nucl. Med. Biol. 2016;43(12):818–826.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Shrivastava S, et al. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep. 2016;6:23179–23113.[27052896.
   PubMed Web of Science ®Google Scholar
• Tekade RK, Sun X. The warburg effect and glucose-derived cancer theranostics. Drug Discov Today. 2017;22(11):1637–1653.
   PubMed Web of Science ®Google Scholar
• Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013;1835(2):164–169.
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654–662.
   PubMed Web of Science ®Google Scholar
• Torres-Pérez SA, del M, Ramos-Godínez P, et al. Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. J. Drug Deliv. Sci. Technol. 2020;58:101769. )
   Web of Science ®Google Scholar
• Pawar SK, Badhwar AJ, Kharas F, et al. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharm. 2012;436(1-2):183–193.
   PubMedGoogle Scholar
• Kumar P, Paknikar KM, Gajbhiye V. A robust pH-sensitive unimolecular dendritic nanocarrier that enables targeted anti-cancer drug delivery via GLUT transporters. Colloids Surf B Biointerfaces. 2018;171:437–444.
   PubMed Web of Science ®Google Scholar
• Satsangi A, Roy SS, Satsangi RK, et al. Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy. Biomaterials. 2015;59:88–101.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm Res. 2015;32(4):1438–1450.
   PubMed Web of Science ®Google Scholar
• Hu G, Chun X, Wang Y, et al. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Oncotarget. 2015;6(38):41258–41274.
   PubMedGoogle Scholar
• Kong X, Yu K, Yu M, et al. A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin. Int J Pharm. 2014;465(1-2):378–387.
   PubMedGoogle Scholar
• Hong P, Li W, Li J. Applications of aptasensors in clinical diagnostics. Sensors (Basel). 2012;12(2):1181–1193.
   PubMed Web of Science ®Google Scholar
• Kazarian A, Blyuss O, Metodieva G, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. 2017;116(4):501–508.
   PubMed Web of Science ®Google Scholar
• Gothwal A, Kesharwani P, Gupta U, et al. Dendrimers as an effective nanocarrier in cardiovascular disease. Curr Pharm Des. 2015;21(30):4519–4526.
   PubMed Web of Science ®Google Scholar
• Li S, Hu R, Yang C, et al. An ultrasensitive bioluminogenic probe of γ-Glutamyltranspeptidase in vivo and in human serum for tumor diagnosis. Biosens Bioelectron. 2017;98:325–329.
   PubMed Web of Science ®Google Scholar
• Even-Desrumeaux K, Baty D, Chames P. State of the art in tumor antigen and biomarker discovery. Cancers (Basel). 2011;3(2):2554–2596.
   PubMedGoogle Scholar
• Chi Y, Yao L, Hu X, et al. The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer. Oncotarget. 2016;7(12):14951–14962.
   PubMedGoogle Scholar
• Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7(3):295–304.
   PubMed Web of Science ®Google Scholar
• Mohammadi S, Salimi A, Hamd-Ghadareh S, et al. A FRET immunosensor for sensitive detection of CA 15-3 tumor marker in human serum sample and breast cancer cells using antibody functionalized luminescent carbon-dots and AuNPs-dendrimer aptamer as donor-acceptor pair. Anal Biochem. 2018;557:18–26.
   PubMed Web of Science ®Google Scholar
• Zhu H, Dale PS, Caldwell CW, et al. Rapid and label-free detection of breast cancer biomarker CA15-3 in clinical human serum samples with optofluidic ring resonator sensors. Anal Chem. 2009;81(24):9858–9865.
   PubMed Web of Science ®Google Scholar
• Mendoza-Nava H, Ferro-Flores G, De María Ramírez F, et al. Fluorescent, plasmonic, and radiotherapeutic properties of the 177Lu-dendrimer-AuNP-folate-bombesin nanoprobe located inside cancer cells. Mol Imaging. 2017;16:153601211770476.
   Web of Science ®Google Scholar
• Zhu J, Zheng L, Wen S, et al. Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials. 2014;35(26):7635–7646.
   PubMed Web of Science ®Google Scholar
• Bellotti E, Cascone MG, Barbani N, et al. Targeting cancer cells overexpressing folate receptors with new terpolymer-based nanocapsules: toward a novel targeted DNA delivery system for cancer therapy. Biomedicines. 2021;9(9):1275.
   PubMed Web of Science ®Google Scholar
• Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2018;9(4):790–810.
   PubMed Web of Science ®Google Scholar
• Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553–52574.
   PubMedGoogle Scholar
• Narmani A, Yavari K, Mohammadnejad J. Imaging, biodistribution and in vitro study of smart 99mTc-PAMAM G4 dendrimer as novel nano-complex. Colloids Surf B Biointerfaces. 2017;159:232–240.
   PubMed Web of Science ®Google Scholar
• Xiong H, Liu S, Wei T, et al. Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo. J Control Release. 2020;325:198–205.
   PubMed Web of Science ®Google Scholar
• Waller J, DeStefano K, Chiu B, et al. An update on nanoparticle usage in breast cancer imaging. Nano Sel. 2022;3(7):1103–1111.
   Google Scholar
• Otis JB, Zong H, Kotylar A, et al. Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells. Oncotarget. 2016;7(24):36002–36013.
   PubMedGoogle Scholar
• Li K, Zhang Z, Zheng L, et al. Arg-Gly-ASP-D-Phe-Lys peptide-modified PEGylated dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of breast carcinoma. Nanomedicine (Lond). 2015;10(14):2185–2197.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu W, Ding B, et al. cRGD mediated redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for efficiently intracellular antitumor drug delivery. Colloids Surf B Biointerfaces. 2020;194:111195.
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Biomarkers for prostate cancer: Prostate-specific antigen and beyond. Clin Chem Lab Med. 2020;58(3):326–339.[31714881.
   PubMed Web of Science ®Google Scholar
• Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med. 2008;2(6):577–586.
   PubMed Web of Science ®Google Scholar
• Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: Achievements, promises, and challenges. J Thorac Oncol. 2019;14(3):343–357.
   PubMed Web of Science ®Google Scholar
• Mousa L, Salem ME, Mikhail S. Biomarkers of angiogenesis in colorectal cancer. Biomark Cancer. 2015;7(Suppl 1):13–19.
   PubMedGoogle Scholar
• Nikolouzakis TK, Falzone L, Lasithiotakis K, et al. Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in Non-Melanoma skin cancer. JCM. 2020;9(9):2868. 20209, page2868.
   Google Scholar
• Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015;122014 12(1):11–26.
   PubMed Web of Science ®Google Scholar
• Marcu LG, Reid P, Bezak E. The promise of novel biomarkers for head and neck cancer from an imaging perspective. IJMS. 2018;19(9):2511. 2018, Vol. 19, Page 2511
   Google Scholar
• Vtorushin SV, Khristenko KY, Zavyalova MV, et al. THE PHENOMENON OF MULTI-DRUG RESISTANCE IN THE TREATMENT OF MALIGNANT TUMORS, 2014.
   Google Scholar
• Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A. 2015;112(10):2978–2983.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu D, Zhang M, et al. The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells. Int J Nanomedicine. 2016;11:3677–3690.
   PubMed Web of Science ®Google Scholar
• Pan L, Liu J, He Q, et al. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials. 2013;34(11):2719–2730.
   PubMed Web of Science ®Google Scholar
• Milane L, Ganesh S, Shah S, et al. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the warburg effect, stem cells, and multifunctional nanotechnology. J Control Release. 2011;155(2):237–247.
   PubMed Web of Science ®Google Scholar
• Xu W, Gao X, Ge P, et al. Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance. Int J Pharm. 2018;553(1-2):349–362.
   PubMedGoogle Scholar
• Wang M, Li Y, Huangfu M, et al. Pluronic-attached polyamidoamine dendrimer conjugates overcome drug resistance in breast cancer. Nanomedicine (Lond). 2016;11(22):2917–2934.
   PubMed Web of Science ®Google Scholar
• Gu J, Fang X, Hao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Biomaterials. 2015;45:99–114.
   PubMed Web of Science ®Google Scholar
• Nguyen TTC, Nguyen CK, Nguyen TH, et al. Highly lipophilic pluronics-conjugated polyamidoamine dendrimer nanocarriers as potential delivery system for hydrophobic drugs. Mater Sci Eng C Mater Biol Appl. 2017;70(Pt 2):992–999.
   PubMedGoogle Scholar
• Gu Y, Guo Y, Wang C, et al. A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. Mater Sci Eng C Mater Biol Appl. 2017;70(Pt 1):572–585.
   PubMed Web of Science ®Google Scholar
• Khakinahad Y, Sohrabi S, Razi S, et al. Margetuximab conjugated-PEG-PAMAM G4 nano-complex: a smart nano-device for suppression of breast cancer. Biomed. Eng. Lett. 2022;2022:1–13.
   Google Scholar
• Pan J, Mendes LP, Yao M, et al. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. Eur J Pharm Biopharm. 2019;136:18–28.
   PubMed Web of Science ®Google Scholar
• Li J, Liu J, Guo N, et al. Reversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes. Int J Pharm. 2016;511(1):436–445.
   PubMedGoogle Scholar
• Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138–7150.
   PubMed Web of Science ®Google Scholar
• de Ruijter TC, Veeck J, de Hoon JPJ, et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183–192.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today. 2015;20(5):536–547.
   PubMed Web of Science ®Google Scholar
• Luong D, Sau S, Kesharwani P, et al. Polyvalent Folate-Dendrimer-Coated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting. Biomacromolecules. 2017;18(4):1197–1209.
   PubMed Web of Science ®Google Scholar
• Hu K, Law JH, Fotovati A, et al. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 2012;14(1):R22.
   Web of Science ®Google Scholar
• Expression of Twist and Wnt in Human Breast Cancer - PubMed, (n.d.).
   Google Scholar
• Wu P-H, Onodera Y, Ichikawa Y, et al. Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells. Int J Nanomedicine. 2017;12:5069–5085.
   PubMed Web of Science ®Google Scholar
• Pandi P, Jain A, Raju S, et al. Therapeutic approaches for the delivery of TNF-α siRNA. Ther Deliv. 2017;8(5):343–355.
   PubMed Web of Science ®Google Scholar
• Ionov M, Wróbel D, Gardikis K, et al. Effect of phosphorus dendrimers on DMPC lipid membranes. Chem. Phys. Lipids. 2012;165(4):408–413. in: Chem Phys Lipids
   PubMed Web of Science ®Google Scholar
• Jain A, Mahira S, Majoral J, et al. Dendrimer mediated targeting of siRNA against polo‐like kinase for the treatment of triple negative breast cancer. J. Biomed. Mater. Res. 2019;107(9):1933–1944. ) jbma
   Web of Science ®Google Scholar
• Liu X, Zhou J, Yu T, et al. Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems. Angew Chem Int Ed Engl. 2014;53(44):11822–11827.
   PubMed Web of Science ®Google Scholar
• Yu T, Liu X, Bolcato-Bellemin A-L, et al. An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo. Angew Chem Int Ed Engl. 2012;51(34):8478–8484.
   PubMed Web of Science ®Google Scholar
• Finlay J, Roberts CM, Lowe G, et al. RNA-Based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int. 2015;2015:382745. ).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ghosal K, Mohammad SA, et al. Dendrimer functionalized carbon quantum dot for selective detection of breast cancer and gene therapy. Chem. Eng. J. 2019;373:468–484.
   Web of Science ®Google Scholar
• Finney L, Mandava S, Ursos L, et al. X-ray flourescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci U S A. 2007;104(7):2247–2252.
   PubMed Web of Science ®Google Scholar
• V P, TG S, K K, et al. Serum levels of metal ions in female patients with breast cancer. J. Clin. Diagn Res. 2015;9:BC25-c27.
   Google Scholar
• Choi JS, Nam K, Park JY, et al. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine. J Control Release. 2004;99(3):445–456.
   PubMed Web of Science ®Google Scholar
• Tung CH, Weissleder R. Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev. 2003;55(2):281–294.
   PubMed Web of Science ®Google Scholar
• Won YW, Yoon SM, Lee KM, et al. Poly(oligo-D-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol Ther. 2011;19(2):372–380.
   PubMed Web of Science ®Google Scholar
• Nam HY, Nam K, Lee M, et al. Dendrimer type bio-reducible polymer for efficient gene delivery. J Control Release. 2012;160(3):592–600.
   PubMed Web of Science ®Google Scholar
• Domański DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry. 2004;63(1-2):189–191.
   PubMed Web of Science ®Google Scholar
• Shcharbin D, Janicka M, Wasiak M, et al. Serum albumins have five sites for binding of cationic dendrimers. Biochim Biophys Acta. 2007;1774(7):946–951.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhao XH, Wang ZY, et al. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett. 2010;298(1):34–49.
   PubMed Web of Science ®Google Scholar
• Nasr M, Nafee N, Saad H, et al. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2014;88(1):216–225.
   PubMed Web of Science ®Google Scholar
• Kotula JW, Pratico ED, Ming X, et al. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther. 2012;22(3):187–195.
   PubMed Web of Science ®Google Scholar
• Taghdisi SM, Danesh NM, Ramezani M, et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm. 2016;102:152–158.
   PubMed Web of Science ®Google Scholar
• won Kim J, jae Lee J, Choi JS, et al. Electrostatically assembled dendrimer complex with a high-affinity protein binder for targeted gene delivery. Int J Pharm. 2018;544(1):39–45.
   PubMedGoogle Scholar
• Yun M, Kim DY, jae Lee J, et al. A high-affinity repebody for molecular imaging of EGFR-expressing malignant tumors. Theranostics. 2017;7(10):2620–2633.
   PubMed Web of Science ®Google Scholar
• Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007;67(17):8156–8163.
   PubMed Web of Science ®Google Scholar
• Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721–725.
   PubMed Web of Science ®Google Scholar
• Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. BIO Integr. 2021;2(2):57–60.
   Google Scholar
• Hua S, de Matos MBC, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. Front Pharmacol. 2018;9:790–714.
   PubMed Web of Science ®Google Scholar
• Debnath S, Saloum D, Dolai S, et al. Dendrimer-curcumin conjugate: a water soluble and effective cytotoxic agent against breast cancer cell lines. Anticancer Agents Med Chem. 2013;13(10):1531–1539.
   PubMed Web of Science ®Google Scholar
• dendrimer-doxorubicin conjugate for enhanced therapeutic effect for cancer - Google Search, (n.d.).
   Google Scholar
• Dendrimerfunctionalizedcarbonquantumdotforselectivedetectionof breastcancerandgenetherapy - Search Results - PubMed, (n.d.).
   Google Scholar
• Lee IH, Yu MK, Kim IH, et al. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy. J Control Release. 2011;155(1):88–95.
   PubMed Web of Science ®Google Scholar
• Pang CT, Ammit AJ, Ong YQE, et al. Para-Sulfonatocalix[4]arene and polyamidoamine dendrimer nanocomplexes as delivery vehicles for a novel platinum anticancer agent. J Inorg Biochem. 2017;176:1–7.
   PubMed Web of Science ®Google Scholar
• Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al. PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: Possible inhibition of telomerase. Asian Pac J Cancer Prev. 2013;14(11):6925–6928.
   PubMedGoogle Scholar
• Matai I, Sachdev A, Gopinath P. Self-assembled hybrids of fluorescent carbon dots and PAMAM dendrimers for epirubicin delivery and intracellular imaging. ACS Appl Mater Interfaces. 2015;7(21):11423–11435.
   PubMed Web of Science ®Google Scholar
• Liu L, Kuang Y, Yang H, et al. An amplification strategy using DNA-Peptide dendrimer probe and mass spectrometry for sensitive MicroRNA detection in breast cancer. Anal Chim Acta. 2019;1069:73–81.
   PubMed Web of Science ®Google Scholar